The Experts below are selected from a list of 264 Experts worldwide ranked by ideXlab platform

Marian Spajdel - One of the best experts on this subject based on the ideXlab platform.

  • Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic.
    Pathogens (Basel Switzerland), 2020
    Co-Authors: Jiři Beran, Marian Spajdel, Věra Katzerová, Alena Holoušová, Jan Malyš, Jana Finger Rousková, J. Slíva
    Abstract:

    During the COVID-19 pandemic, the elderly population has been disproportionately affected, especially those in nursing homes (NH). Inosine Pranobex (IP) has been previously demonstrated to be effective in treating acute viral respiratory infections. In three NH experiencing the SARS-CoV-2 virus epidemic, we started treatment with IP as soon as clients tested PCR+. In Litovel, CZ, the difference in case-fatality rate (CFR) for the PCR+ group using vs. not using IP was statistically significant, and the odds ratio (OR) was 7.2. When comparing all those taking IP in the three NH vs. the non-drug PCR+ group in Litovel, the odds ratio was lower for all three NH, but still significant at 2.9. The CFR in all three tested NHs, age range 75-84, compared to the CFR in all NHs in the Czech Republic, was significantly reduced (7.5% vs. 18%) (OR: 2.8); there was also a significant difference across all age groups (OR: 1.7). In our study with 301 residents, the CFR was significantly reduced (OR: 2.8) to 11.9% (17/142) in comparison to a study in Ireland with 27.6% (211/764). We think the effect of IP was significant in this reduction; nevertheless, these are preliminary results that need larger-scale trials on COVID-19 patients.

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections analysis and subgroup analysis from a phase 4 randomised placebo controlled double blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI <30 kg/m2). The differences between the Inosine Pranobex and placebo groups in subjects at least 50 years of age without related ongoing disease and in subjects less than 50 years of age who were obese (BMI ≥30 kg/m2) were not statistically significant. Inosine Pranobex was generally well tolerated, and no deaths were reported. The study results indicate the safety of Inosine Pranobex for the treatment of subjects with confirmed acute respiratory viral infections and confirm the efficacy of Inosine Pranobex versus placebo in healthy non-obese subjects less than 50 years of age with clinically diagnosed influenza-like illnesses. EWO-ISO-2014/1, EudraCT 2014-001863-11 ; Date of registration: 29 APR 2014; Detail information web link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001863-11/results

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Background Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. Methods A total of 463 subjects were randomly assigned to receive Inosine Pranobex ( n  = 231) or placebo ( n  = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. Results The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P -value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC infectious diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

Jiři Beran - One of the best experts on this subject based on the ideXlab platform.

  • Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic.
    Pathogens (Basel Switzerland), 2020
    Co-Authors: Jiři Beran, Marian Spajdel, Věra Katzerová, Alena Holoušová, Jan Malyš, Jana Finger Rousková, J. Slíva
    Abstract:

    During the COVID-19 pandemic, the elderly population has been disproportionately affected, especially those in nursing homes (NH). Inosine Pranobex (IP) has been previously demonstrated to be effective in treating acute viral respiratory infections. In three NH experiencing the SARS-CoV-2 virus epidemic, we started treatment with IP as soon as clients tested PCR+. In Litovel, CZ, the difference in case-fatality rate (CFR) for the PCR+ group using vs. not using IP was statistically significant, and the odds ratio (OR) was 7.2. When comparing all those taking IP in the three NH vs. the non-drug PCR+ group in Litovel, the odds ratio was lower for all three NH, but still significant at 2.9. The CFR in all three tested NHs, age range 75-84, compared to the CFR in all NHs in the Czech Republic, was significantly reduced (7.5% vs. 18%) (OR: 2.8); there was also a significant difference across all age groups (OR: 1.7). In our study with 301 residents, the CFR was significantly reduced (OR: 2.8) to 11.9% (17/142) in comparison to a study in Ireland with 27.6% (211/764). We think the effect of IP was significant in this reduction; nevertheless, these are preliminary results that need larger-scale trials on COVID-19 patients.

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections analysis and subgroup analysis from a phase 4 randomised placebo controlled double blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI <30 kg/m2). The differences between the Inosine Pranobex and placebo groups in subjects at least 50 years of age without related ongoing disease and in subjects less than 50 years of age who were obese (BMI ≥30 kg/m2) were not statistically significant. Inosine Pranobex was generally well tolerated, and no deaths were reported. The study results indicate the safety of Inosine Pranobex for the treatment of subjects with confirmed acute respiratory viral infections and confirm the efficacy of Inosine Pranobex versus placebo in healthy non-obese subjects less than 50 years of age with clinically diagnosed influenza-like illnesses. EWO-ISO-2014/1, EudraCT 2014-001863-11 ; Date of registration: 29 APR 2014; Detail information web link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001863-11/results

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Background Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. Methods A total of 463 subjects were randomly assigned to receive Inosine Pranobex ( n  = 231) or placebo ( n  = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. Results The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P -value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC infectious diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

Eva Salapova - One of the best experts on this subject based on the ideXlab platform.

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections analysis and subgroup analysis from a phase 4 randomised placebo controlled double blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI <30 kg/m2). The differences between the Inosine Pranobex and placebo groups in subjects at least 50 years of age without related ongoing disease and in subjects less than 50 years of age who were obese (BMI ≥30 kg/m2) were not statistically significant. Inosine Pranobex was generally well tolerated, and no deaths were reported. The study results indicate the safety of Inosine Pranobex for the treatment of subjects with confirmed acute respiratory viral infections and confirm the efficacy of Inosine Pranobex versus placebo in healthy non-obese subjects less than 50 years of age with clinically diagnosed influenza-like illnesses. EWO-ISO-2014/1, EudraCT 2014-001863-11 ; Date of registration: 29 APR 2014; Detail information web link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001863-11/results

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC Infectious Diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Background Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. Methods A total of 463 subjects were randomly assigned to receive Inosine Pranobex ( n  = 231) or placebo ( n  = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. Results The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P -value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

  • Inosine Pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
    BMC infectious diseases, 2016
    Co-Authors: Jiři Beran, Eva Salapova, Marian Spajdel
    Abstract:

    Inosine Pranobex (IsoprInosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of Inosine Pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of Inosine Pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. A total of 463 subjects were randomly assigned to receive Inosine Pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the Inosine Pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the Inosine Pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI

V.a. Bulgakova - One of the best experts on this subject based on the ideXlab platform.

  • Acute and Recurrent Respiratory Tract Infections: Possible Reduction of the Patient’s Pill Burden
    "Paediatrician" Publishers LLC, 2015
    Co-Authors: V.a. Bulgakova
    Abstract:

    Acute and recurrent respiratory tract infections in children are often the reason for seeking medical help. Frequent and prolonged respiratory infections in childhood may lead to the subsequent formation of chronic respiratory diseases in adults. Susceptibility to respiratory infections is common in children with allergic diseases and other chronic diseases accompanied by a decrease in immune reactivity. In the case of acute respiratory infection, these patients, in addition to the basic treatment of the underlying disease, have to take additional cough medicines that increase the pill burden on the body. The main causative agents of acute respiratory infections are viruses. Inosine Pranobex is a drug with antiviral and immunomodulatory effects. The article describes the pharmacological properties and the results from studying the efficacy of Inosine Pranobex in the treatment of acute respiratory viral infections in children

  • Antiviral Therapy for Acute Respiratory Infections in Children
    Publishing House Zaslavsky, 2014
    Co-Authors: V.a. Bulgakova
    Abstract:

    It is shown that administration of Inosine Pranobex reduces the symptoms of acute respiratory viral infection, duration of the disease, prevents complications and restores compromised immunity. The drug is effective not only in the first hours of the disease, but also in the subsequent period

  • ACUTE RESPIRATORY TRACT INFECTIONS: WIDENING OF POSSIBILITIES OF ANTIVIRAL TREATMENT
    "Paediatrician" Publishers LLC, 2013
    Co-Authors: V.a. Bulgakova
    Abstract:

    Problem of effective and safe treatment and prophylaxis of acute respiratory tract infections is one of the most topical problems in clinical pediatrics. In this article the possibility of usage in treatment of acute respiratory viral infections an immunostimulating drug with antiviral action — Pranobex. The author describes mechanisms of combined immunomodulatory and antiviral action of this drug, shows data on its efficacy and tolerability in children. The demonstrated data of literature review and the results of the author’s own studies evidenced that administration of Inosine Pranobex relieved symptoms of acute respiratory viral infection, prevent development of complications and restores the weakened immunity, allows decreasing of the requirements of other drugs and medicinal load to the organism. Characteristics of this drug widen the possibilities of pharmacotherapy of acute respiratory viral infections in children. Anaysis of publications on efficacy of this drug, as well as the author’s own data allow to recommend Inosine Pranobex for treatment of acute respiratory tract infections in frequently ill children, patients with chronic diseases (including allergic disorders of the respiratory tract) and intercurrent acute respiratory tract infections

  • CLINICAL AND IMMUNOLOGICAL EFFICACY OF Inosine Pranobex FOR ACUTE RESPIRATORY INFECTIONS IN CHILDREN WITH ATOPIC ASTHMA
    Paediatrician Publishers LLC, 2010
    Co-Authors: V.a. Bulgakova, I.i. Balabolkin, S.g. Shmakova, I.v. Zubkova, E.l. Korol'kova
    Abstract:

    The prevalence rate of atopic asthma in children remains high. One of the reasons for lack of control over asthma symptoms is repeated infection. The article describes results from the study of immunomodulating medication Inosine Pranobex used in treatment of acute respiratory infections in children with atopic asthma. The results obtained prove the efficacy and safety of this medication. The use of this immunomodifier with antiviral activity during the period of acute respiratory infection in children with atopic asthma contributes to shortening of intoxication and catarrhal signs duration, elimination of viral agents. Key words: asthma, acute respiratory infections, immunomodifiers, Inosine Pranobex, children. (Pediatric Pharmacology. – 2010; 7(3):98-105

  • ASSESSMENT OF THE EFFICACY OF COMBINED EFFECT IMMUNOMODULATOR Inosine Pranobex IN PREVENTING RESPIRATORY INFECTIONS IN CHILDREN WITH ALLERGIES
    Paediatrician Publishers LLC, 2010
    Co-Authors: V.a. Bulgakova, I.i. Balabolkin, L.k. Katosova, I.v. Zubkova
    Abstract:

    Among children with allergies, particularly with bronchial asthma, patients susceptible to frequent acute respiratory infections make up a large group. In recent years, a strong focus has been on persistency of viruses and other pathogenic microorganisms in various areas of the respiratory tract, which leads to change in responsiveness of the organism and warrants the practicability of applying agents with a combined immunomodulating and antiviral effect. The purpose of this study was to assess the clinical and immunological efficacy of Inosine Pranobex in children with bronchial asthma and frequent respiratory infections. 37 children with atopic persistent moderate asthma at ages 4 to 15 were examined, 26 of which were administered Inosine Pranobex orally in prevention dosages at 50 mg/kg twice a day over 14 days. The control group was made up of 11 children who were on no immunopharmacological prevention course. Virus antigens in nasopharyngeal smear samples were identified, cytokine status and antibody immune response were studied. In the main group, 23 children (88,5%) were found to have the frequency and length of intercurrent acute respiratory viral infections decreased 1,5 times (p < 0,05) and the number of asthma attacks decreased 1,7 times (p < 0,05). The obtained results demonstrate the efficacy of preventing respiratory infections with Inosine Pranobex in children with bronchial asthma and other allergic diseases. Key words: acute respiratory infections, allergy, bronchial asthma, children, prevention, immunomodulators, Inosine Pranobex. (Pediatric Pharmacology. – 2010; 7(5):30-37

Banu Anlar - One of the best experts on this subject based on the ideXlab platform.

  • Subacute Sclerosing Panencephalitis
    CNS Drugs, 1997
    Co-Authors: Banu Anlar
    Abstract:

    Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imaging studies and measles antibody synthesis rate in the CSF provide supportive laboratory data. When CSF studies are negative, a brain biopsy is indicated to assess the presence of inclusion bodies, measles virus antigens or viral RNA. Among the many drugs and methods tried in the treatment of SSPE, the highest rate of stabilisation or improvement has been obtained with intraventricular interferon-α (interferon-alfa) and oral Inosine Pranobex. Further research, including multicentre clinical trials, is warranted to identify more efficient therapeutic regimens.

  • subacute sclerosing panencephalitis diagnosis and drug treatment options
    CNS Drugs, 1997
    Co-Authors: Banu Anlar
    Abstract:

    Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imaging studies and measles antibody synthesis rate in the CSF provide supportive laboratory data. When CSF studies are negative, a brain biopsy is indicated to assess the presence of inclusion bodies, measles virus antigens or viral RNA.Among the many drugs and methods tried in the treatment of SSPE, the highest rate of stabilisation or improvement has been obtained with intraventricular interferon-α (interferon-alfa) and oral Inosine Pranobex. Further research, including multicentre clinical trials, is warranted to identify more efficient therapeutic regimens.